Previous studies have identified several clinical factors such as dermoscopic hemorrhagic dots and BMI at baseline that influence the response to anti-TNF-α therapy in psoriasis (Lallas et al., 2016; Zweegers et al., 2017). Here, TNF is linked to psoriasis.